Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines, and animal health products. The company's operations are managed on a product basis and include two operating segments: pharmaceutical and animal health. Merck's performance reflects strong execution of its science-led strategy, benefiting from strong underlying demand across its innovative portfolio and disciplined investments to leverage leading-edge science. The company continues to execute strategic business development opportunities to augment its robust internal pipeline with compelling external science. Merck's capital allocation strategy prioritizes investments in its business to drive near- and long-term growth, including addressing important unmet medical needs and supporting commercial opportunities. The company remains committed to its dividend and will pursue compelling external science and technologies through value-enhancing business development transactions. Merck's strong financial profile enables it to fund research and development, finance acquisitions and external alliances, and maximize upcoming launches while providing significant cash returns to shareholders. The company anticipates that foreseeable liquidity and capital resource requirements will be met through existing cash and cash equivalents and anticipated cash flows from operations. Merck actively monitors the landscape for growth opportunities that meet its strategic criteria, indicating a proactive approach to resilience in the face of market challenges. The company has engaged in several acquisitions and collaborations to enhance its capabilities and adapt to changing market conditions, demonstrating its commitment to resilience strategies. The company's research and development expenses reflect increased spending, particularly in therapeutic areas such as oncology, cardiovascular, infectious diseases, and vaccines, highlighting its focus on innovation and adaptability. Merck's operational flexibility is evidenced by its ability to respond to external pressures, including changes in the health care system and pricing pressures, which have exerted significant impacts on product pricing and market access worldwide. The company has also implemented additional quality controls to ensure compliance with health authorities, reflecting its commitment to maintaining operational integrity under challenging conditions. Merck's strategic initiatives include diversifying its oncology portfolio and executing on its strategy based on three pillars: immuno-oncology, precision molecular targeting, and tissue targeting. The company continues to adapt its operational management to optimize supply reliability and increase efficiency, demonstrating its resilience in navigating complex situations and environmental disruptions. The company's restructuring programs are aimed at optimizing its manufacturing and supply network, further illustrating its commitment to maintaining performance under pressure and ensuring organizational health. Through these strategic responses, Merck aims to enhance its organizational resilience, ensuring its ability to absorb strain and preserve functioning despite adversity.